Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
7Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
ImageneBio, Inc. (IMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
5High confidence
0.770Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
ImageneBio, Inc. Suppliers
Ticker
Name
Confidence
Evidence
HUTCHMED
HUTCHMED
90%
Our licenses from Hutchmed and WuXi Biologics are limited to intellectual property rights owned or controlled by such licensors.
WUXI-BIOLOGICS
WUXI-BIOLOGICS
90%
Our licenses from Hutchmed and WuXi Biologics are limited to intellectual property rights owned or controlled by such licensors.
Reciprocal relationship from NKTR graph: Reciprocal relationship from IMA graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from IMA graph: ntures or collaborations, or enter in…
ntures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to I…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMA graph: ntures or collaborations, or enter …
SNYNF
Sanofi
72%
ntures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to I…
CELEXOR-BIO-INC
CELEXOR-BIO-INC
62%
(the “Celexor Agreement”) with Celexor Bio, Inc. (“Celexor”). Legacy Inmagene granted Celexor an exclusive royalty-bearing license to develop, manufacture, and commercialize any and all products and …
HUTCHINSON-MEDIPHARMA-LIMITED
HUTCHINSON-MEDIPHARMA-LIMITED
62%
authorities of individual EU Member States or comparable foreign regulatory authorities to perform additional preclinical studies and clinical trials or to modify any of our manufacturing processes o…
HUTCHMED-LIMITED
HUTCHMED-LIMITED
62%
authorities of individual EU Member States or comparable foreign regulatory authorities to perform additional preclinical studies and clinical trials or to modify any of our manufacturing processes o…
ImageneBio, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IMA-DEBT-10227
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
IMA-DEBT
Debt stack $2.4M
90%
Market cache reports total debt of $2.4M.
ImageneBio, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for ImageneBio, Inc..
ImageneBio, Inc. Ownership
Holder
Name
Confidence
Evidence
IMA-OWNER-BVF-INC-IL
BVF INC/IL
90%
13F overlay lists BVF INC/IL as top holder; 38 tracked holders.
